CooperCompanies Insiders Buy as reset forms rebind

Important Points
- CooperCompanies insiders bought shares in late 2025, highlighting the possibility of a price rebound in early 2026.
- Analysts and institutions are flocking to the stock, and its price is set to reverse course as the year progresses.
- Cash returns, especially share buybacks, provide leverage and increase value for investors, which supports a strong stock price outlook again.
CooperCompanies (NASDAQ: COO) insiders showed confidence in the company’s growth outlook by buying shares in December, extending a trend that began last month. Insiders, including the CEO, several directors, and other influential C-suite executives, bought shares while they were in a long-term crisis, causing a rebound, but the story didn’t end there.
COO’s price action pulled back in early March, following an otherwise healthy earnings report, providing another opportunity to get into this stock. Headwinds remain, but the long-term outlook is bullish, including growth, profitability, and capital returns.
CooperCompanies is well positioned to drive growth and cash flow as a leading consumer-focused medical device company. The devices are offered in two lines, including vision and women’s/family health. The vision segment is best known for its contact lenses, which are highly regarded and often ranked among the top three worldwide. The women’s health department is also widely regarded as having a major role in contraception, fertility, and gynecology. Long-term forecasts suggest a pace of mid- to mid-single-digit income growth over the next decade, with incomes growing at a slightly faster pace.
Capital Returns Keep Analysts and Institutions Interested in COO Stock
CooperCompanies’ majority dividend consists of share repurchases, but it is large, sustainable, and offers growing leverage to investors. Financial activity for Q1 2026, in addition to purchases in previous quarters, resulted in a decline of approximately 2.25% year-on-year (YOY), a pace that is expected to continue in the coming quarters.
The balance does not provide red flags for investors, only reasons to buy the stock. End-of-quarter highlights include increased cash and assets, reduced debt and liabilities, and a rising stock price despite aggressive cash-backs. Equity rose 1.5%, and profits are flat, suggesting the company can continue to execute on its strategy. The strategy includes expanding and developing product lines and pursuing targeted acquisitions. CooperCompanies has a history of selectively acquiring high-quality, niche products that enhance their core functional areas.
Analyst trends reflect the quality of this business. They show high confidence, giving it an Average buy rating. While one Sell rating is included, the bullish bias is 50% Buy and 49% Hold, with trends showing increasing coverage on a trailing 12-month (TTM) basis, and the price target is firming following the March earnings update. As it stands, the consensus is predicting a 25% increase from early March, and higher highs are likely. A move to the $90 consensus is enough to set a long-term high, break above key resistance, and put the market on the path to a complete reversal.
Technology Reversals Are in Play: The Head and Shoulders Revolution is Underway
The pattern is far from complete, but the price action in COO stock, given its fundamentals and growth outlook, suggests that a head and shoulders change is underway. The first shoulder formed in early 2025, the pattern reared its head during the year, and now the second shoulder is forming. There is a risk that the market will continue to decline, possibly breaking support at $70 or $65, but that seems unlikely given the outlook, cash flow, and capital return.
Institutional trends are another reason to believe that this health care stock is in the midst of a complete reversal. Institutional holdings remain relatively simple at 25%, but the group is accumulating shares and activity is growing. The only bad news is that selling is picking up next to buying, albeit slowly, and may keep volatility high until another stimulus emerges. Among the possible triggers is the completion of a strategic review. Started last year, it brought an element of uncertainty to the vision and will go a long way in reviving the market’s enthusiasm once it is completed.
CooperCompanies bounces back after strong report
CooperCompanies posted a strong Q1 release, with top and bottom results leading the consensus rating. Details such as narrowing of gross margin caused by pricing were corrected by operational and behavioral improvements, resulting in increased profit margins. The bottom line is that adjusted earnings growth is close to 20% for the quarter and will likely continue at moderate rates as the year progresses. The guide, which is improved compared to the previous guide, is also possible to notice. The momentum in new healthcare product lines such as MyDay and MiSight, which help slow the progression of nearsightedness in children, supports the view.

Companies in this article:
| Company | Current Price | Price Changes | Dividend Yield | The P/E ratio | Consensus ratio | Consensus Price Target |
|---|---|---|---|---|---|---|
| Cooper Companies (COO) | $75.82 | -1.0% | N/A | 37.53 | Buy Medium | $90.79 |



